Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Neoplasm Metastasis 2Breast Neoplasms 2Thyroid Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lung Neoplasms 1Colonic Neoplasms 1Breast Neoplasms, Male 1

Interventions

Paclitaxel 50Capecitabine 50Trastuzumab 38Fulvestrant 31pembrolizumab 27Cyclophosphamide 27Carboplatin 27Gemcitabine 23Letrozole 21palbociclib 19Docetaxel 19Lapatinib 18Bevacizumab 18exemestane 17eribulin 15Everolimus 14abemaciclib 13Vinorelbine 13Nivolumab 13Magnetic Resonance Spectroscopy 12Cisplatin 12Anastrozole 12trastuzumab deruxtecan 11Zoledronic Acid 11Doxorubicin 11Albumin-Bound Paclitaxel 11olaparib 10Tamoxifen 10Specimen Handling 10Radiotherapy 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × methyl N-acetylsibirosaminide × Breast × Clear all
NCT02751528 2025-01-13

QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer

NantBioScience, Inc.

Phase 1 Terminated
3 enrolled 10 charts
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Breast Neoplasms, Male

NCT03127098 2024-08-06

QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer

NantCell, Inc.

Phase 1/2 Terminated
3 enrolled 6 charts
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡